This morning I came across Cellzome’s website and on further exploration I think it’s an excellent example of a technology platform company that’s got it right. You don’t see many of these, and I think it serves as a good role model to learn from.

Firstly, The Thing That Attracted Me: Presentation

Cellzome’s website is small, simple and a similar website would be inexpensive to develop (around £7K including content). Its simplicity and clarity is what makes it special. No heavy word-ridden content; just clear and simple messages:

• a small molecule drug discovery technology platform using chemoproteomics for epigenetic and

…

Read more ...

Last week I got a call from an old friend and ex-colleague who bemoaned about how the marketing tactics at his very large life science technology company had pretty much reduced to a handle-turning exercise that was no longer working. Open rates on their emails had fallen to an all-time low, social media efforts were “unproven”, leads coming in from phone and website had dropped off.

When you look at a problem like this, it’s tempting to respond by changing the tactics, refreshing the branding and content, and give the marketing campaigns a “reboot”. Try a webinar series, a workshop, …

Read more ...

In this excellent post, Michele Ollier artfully presents the reasons that early stage R&D companies must focus rather than diversify.

Any molecule early in development is not yet an asset, but it is already a “cash burner”. Michele Ollier, Index Ventures

If you look at the history of many early stage R&D companies, they often begin with a portfolio of projects/technology brought in by the founders. It makes the task of focus (i.e. ditching less viable projects) incredibly difficult because it involves real people who have strong affiliations and insecurities (what will happen to them if project X is …

Read more ...